Valeant Pharmaceuticals Announces Planned Management Departure - 21 News Now, More Local News for Youngstown, Ohio -

Valeant Pharmaceuticals Announces Planned Management Departure

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Valeant Pharmaceuticals International, Inc.

LAVAL, Quebec, June 13, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that Ryan Weldon, Valeant's Executive Vice President and Company Group Chairman, will be leaving the Company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant to Nestlé S.A.  Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the acquired assets through Galderma. 

"The Board of Directors and I appreciate the significant contributions Ryan has made during his time with Valeant, especially his efforts through the Medicis integration and his tireless dedication with the aesthetic and dermatology communities," said J. Michael Pearson, chairman and chief executive officer.  "As a clear testament to the performance of Valeant's aesthetic commercial team, Galderma is in discussions with the injectable team to discuss long-term opportunities.  Although his leadership will be missed, the company has created and developed a strong management team and I am confident Ryan will assist us successfully through this transition period."

"The last six years at Valeant has been an extraordinary experience," said Ryan Weldon.  "It has been a privilege to work with Mike, my fellow Valeant employees, and the Board on this journey."

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology  and branded generics. More information about Valeant can be found at www.valeant.com.

Forward-looking Statements

This press release may contain forward-looking statements, including, but not limited to, statements regarding the long-term opportunities at Galderma for the aesthetics team. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact Information:
Valeant Pharmaceuticals:
Investors:                                                                   
Laurie W. Little
Valeant Pharmaceuticals International, Inc.                                                       
949-461-6002                                                             
laurie.little@valeant.com                                           

Media:
Renee E. Soto/Meghan Gavigan
Sard Verbinnen & Co.
212-687-8080
rsoto@sardverb.com / mgavigan@sardverb.com

Valeant Pharmaceuticals International, Inc.

 Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

©2012 PR Newswire. All Rights Reserved.

  • More From wfmj.comMore>>

  • US warns against traveling to Ebola-hit countries

    US warns against traveling to Ebola-hit countries

    Friday, August 1 2014 10:52 PM EDT2014-08-02 02:52:19 GMT
    United States issues travel warning for three African countries hit by Ebola outbreak.More >>
    U.S. health officials on Thursday warned Americans not to travel to the three West African countries hit by an outbreak of Ebola.More >>
  • US job growth eases but tops 200K for a 6th month

    US job growth eases but tops 200K for a 6th month

    Friday, August 1 2014 5:59 PM EDT2014-08-01 21:59:07 GMT
    U.S. employers extended this year's hiring surge into July by adding a solid 209,000 jobs. It was the sixth straight month of job growth above 200,000, evidence that businesses are shedding the caution that had...More >>
    A sixth straight month of solid 200,000-plus job growth in July reinforced growing evidence that the U.S. economy is accelerating after five years of sluggish expansion.More >>
  • GM boosted June sales with discounts to dealers

    GM boosted June sales with discounts to dealers

    Friday, August 1 2014 9:42 AM EDT2014-08-01 13:42:40 GMT
    By TOM KRISHER Associated Press Auto Writer As General Motors prepares to report monthly sales results on Friday, a look its numbers from June show just how intent the company is on keeping...More >>
    By TOM KRISHER Associated Press Auto Writer As General Motors tackles a safety crisis, a look its numbers from June show just how intent the company is on keeping new-car sales on the rise during a record...More >>
Powered by WorldNow
All content © Copyright 2000 - 2014 Worldnow and WFMJ. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms